Laura Riley
Internal Medicine · Hillsborough, NJNPI 1659725083
Payments from drug & device makers
Across 84 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$295
- Novo Nordisk$192
- Biohaven Pharmaceuticals, Inc.$145
- GSK$110
- Lilly USA, LLC$104
- Astellas Pharma US Inc$100
- plus $545 from 16 others
What the payments were for
- Food & beverage$1,39293%
- Education$1007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $295 |
| Novo Nordisk | 12 | $192 |
| Biohaven Pharmaceuticals, Inc. | 3 | $145 |
| GSK | 7 | $110 |
| Lilly USA, LLC | 7 | $104 |
| Astellas Pharma US Inc | 1 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| Pfizer | 5 | $80 |
| Amgen | 5 | $72 |
| AstraZeneca | 4 | $55 |
| Bayer | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$1,492 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $14,642 |
| JanuviaSitagliptin Phosphate | 11 | $11,655 |
| Levothyroxine Sodium | 33 | $633 |
| Rosuvastatin Calcium | 20 | $320 |
| Amlodipine Besylate | 29 | $243 |
| Atorvastatin Calcium | 33 | $215 |
| Alprazolam | 20 | $128 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $124 |
| Metformin Hcl ErMetformin Hcl | 15 | $118 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $101 |
| Losartan Potassium | 16 | $98 |
| Simvastatin | 11 | $96 |
| Azithromycin | 34 | $69 |
| Metformin Hcl | 13 | $56 |
| Hydrochlorothiazide | 14 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $55 | $14,64212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Hillsborough
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.